Europeiska unionen - italienska - EMA (European Medicines Agency)

eurocept international b. v. - para-amminosalicilico - tubercolosi - antimicobatterici - granupas è indicato per l'uso come parte di un regime di combinazione appropriata per la tubercolosi multi-farmaco resistente in pazienti adulti e pediatrici da 28 giorni di età e più anziani quando un regime terapeutico efficace altrimenti non può essere composta per motivi di resistenza o tollerabilità (vedere paragrafo 4. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Europeiska unionen - italienska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 0.375 mg corresp. pramipexolum 0.26 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 0.750 mg corresp. pramipexolum 0.52 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 1.500 mg corresp. pramipexolum 1.05 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 3.000 mg corresp. pramipexolum 2.1 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 4.500 mg corresp. pramipexolum 3.15 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

heider ag - xenonum(133-xe) - gas zur inhalation - xenonum(133-xe) 74 -740 mbq, gasum inhalationis, pro vitro. - lungenszintigraphie - radiopharmazeutika

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

montefarmaco otc s.p.a. - clordiazepossido - clordiazepossido

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

laboratorio farmacologico milanese s.r.l. - clordiazepossido - clordiazepossido